Sudan ebolavirus antigens (SUDV antigens)

Sudan ebolavirus (SUDV) antigens are the structural and functional proteins of the Sudan ebolavirus, the causative agent of Sudan virus disease (SVD), a severe hemorrhagic fever [1, 16]. The primary therapeutic target among these is the surface glycoprotein (GP), a trimeric spike responsible for viral attachment to host cells and membrane fusion through interactions with the Niemann-Pick C1 (NPC1) receptor [2, 10]. SUDV also encodes several other critical antigens, including the nucleoprotein (NP), which encapsulates the viral RNA, and viral proteins such as VP35 and VP24 that inhibit host innate immune signaling [5, 17]. A unique feature of ebolavirus pathogenesis is the production of a secreted glycoprotein (sGP), which acts as an immunological decoy by absorbing neutralizing antibodies intended for the surface GP [4, 9]. Therapeutic development focuses on neutralizing GP-mediated entry with monoclonal antibody cocktails, such as MBP134 or MBP431, and inhibiting viral replication using small-molecule antivirals like remdesivir or its oral prodrug obeldesivir [8, 11, 14]. These antigens also serve as the basis for various vaccine candidates, including the chimpanzee adenovirus vector vaccine cAd3-EBO S, which aims to elicit protective immune responses during outbreaks [12, 19].

Other names

Sudan virus (SUDV) proteinsSudan ebolavirus surface glycoproteinSUDV GPSudan virus antigensSUDV antigens

Viral entry inhibition, Neutralization of surface glycoprotein, Viral RNA-dependent RNA polymerase inhibition, Induction of protective adaptive immunity